Another interesting study is termed, -Pleural mesothelioma of connective tissue type, localized fibrous tumour in the pleura, and reactive submesothelial hyperplasia. An immunohistochemical comparison- by Moutaiz Al-Izzi, Nicola P. Thurlow, Professor Bryan Corrin – The Journal of Pathology Volume 158, Issue 1, pages 41-44, May 1989. This is an excerpt: -Abstract – Ten diffuse pleural mesotheliomas of connective tissue type have been compared with 14 examples of pleural granulation tissue and 7 localized fibrous tumours in the pleura, using immunohistochemistry to distinguish cytokeralins oflow and high molecular weight and vimentin. Low molecular weight cytokeratin and vimentin were both delected in 8 within the 10 mesotheliomas also in 12 of your 14 reactive iesions. High molecular weight cylokeratin was rarely detected option of lesion. The seven localized fibrous tumours with the pleura were all positive for virnentin and negative for both cytokeratins. These findings support an origin of ligament type mesotheliomas from multipotential submesothelial spindle cells properly localized fibrous tumours belonging to the pleura from either conventional fibroblasts or resting submesothelial spindle cells. Antibodies to cytokeratin help distinguish both these neoplasms but provide no assistance with the much harder diagnostic problem of distinguishing mesotheliomas of connective tissue type from pleural reactions observed as a abundant granulation tissue.-
Another interesting study is named, -Final analysis on the multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)- – Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting edition). Vol 25, No 18S (June 20 Supplement), 2007: 7526 by T. Karrison, H. L. Kindler, D. R. Gandara, C. Lu, T. L. Guterz, K. Nichols, H. Chen, W. M. Stadler and E. E. Vokes – University of Chicago Infirmary, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; MD Anderson Cancer Center, Houston, TX; CTEP National Cancer Institute, Rockville, MD. Here is an excerpt: -Background: In phase II trials in MM, GC at a 21-day (D) schedule has response rates of 16%-26% and median overall survival (OS) of 9.6-13 months (mo). Since VEGF possesses a key role in MM biology, we added anti-VEGF antibody B to GC in a multi-center, double- blind, placebo-controlled randomized phase II trial. Methods: Eligible pts had unresectable MM; no prior chemotherapy; PS 0-1; no thrombosis, bleeding, or major vessel invasion. Primary endpoint: progression-free survival (PFS). Statistics: 90% capability detect HR 0.57. Stratification: PS (0/1), histology (epithelial/other). G 1,250 mg/m2 D 1, 8 Q21D, C 75 mg/m2 D1 Q21D, and B 15 mg/kg or P D1 Q21D was presented x 6 cycles, then B or P Q21D until progression. Baseline plasma VEGF was measured. 115 pts enrolled 12/01- 07/05 at 11 sites, 108 (GCB/GCP) 53/55 were evaluable. Male 74%/84%; median age 62/65 (range 44-78/20-84); PS 1 55%/47%; epithelial 74%/67%; pleural 93%/91%; thrombocytosis 40%/40%. Results: Cycles: total 458/424, median 7/6, range 1-42/2-39. Statistically significantly different (SSD) toxicity (p
Another interesting study is recognized as, -Technique for external beam solution for Mesothelioma- by G.J. Kutcher, PH.D., C. Kestler, R.T., D. Greenblatt, M.D., H. Brenner, M.D., B.S. Hilaris, M.D., D. Nori, M.D. – Volume 13, Issue 11, Pages 1747-1752 (November 1987). Here##Q##s an excerpt: -Abtract – A combined photon-electron beam strategy to diffuse pleural mesothelioma is discussed within this paper. The technique features parallel opposed 10 MV X rays prescribed to 4250 cGy using customized blocks to shield the lung. The pleura will likely be boosted with electrons to some dose of 3600 cGy. The combo yields a TDF of 74 ret towards the pleura. As discussed in the earlier paper, botox cosmetic injections method when put together with subtotal pleurectomy and I-125 implantation will cause improved survivals with minimal complications. The important points in this 3-dimensional radiation treatment method have not been described in greater detail. To increase target coverage and native control, the process has long been modified. CT is already used along with simulation plane films to define the entire pleural surface. The goal volume has additionally extended on the dome for the base of your diaphragm. These changes have ended in improved pleural dose distributions; by blocking the liver or stomach, and boosting the crus from the diaphragm with electrons, there is little change added morbidity. As it is demonstrated by dose volume histograms, we##Q##re allowed to deliver 4250 cGy 10% to the in the pleura with ; on the lung parenchyma receiving not as much as 2100 cGy.-
Another interesting study is named, -Laparoscopy: A key tool in the staging of malignant pleural Mesothelioma- by Kevin C. Conlon, Valerie W. Rusch and Susan Gillern – Annals of Surgical Oncology Volume 3, Number 5, 489-494, DOI: 10.1007 – The following is an excerpt: -Abstract – Background: The current standard to the noninvasive staging of patients with malignant pleural mesothelioma is computed tomography (CT). However, CT often cannot determine whether a tumor is unresectable on account of direct extension throughout the diaphragm towards the peritoneal cavity. The intention of this prospective study would have been to decide if laparoscopy detected transdiaphragmatic tumor extension when CT findings were equivocal.
Methods: From June 1993 to July 1994, 12 of 36 patients considered for possible thoracotomy and surgical resection had equivocal CT findings of diaphragmatic invasion. All underwent laparoscopy having a multiport technique with diaphragmatic and peritoneal biopsies.
Results: The mean operative time was 83 min. They had no perioperative complications. The median stay in hospital was A day. Six patients had biopsy-proven transdiaphragmatic extension, or peritoneal studding of tumor. The additional six patients subsequently underwent thoracotomy: three possessed a complete resection, and three had unresectable tumor on account of chest wall (N=2) or mediastinal (N=1) invasion. In no case was transdiaphragmatic extension associated with a tumor seen.
Conclusions: This preliminary experience implies that laparoscopy is usually a safe and accurate opportinity for detecting transdiaphragmatic tumor extension when CT will not achieve this. Laparoscopy should be thought about a standard a natural part of prethoracotomy staging in this particular subset of patients.-
Monty Wrobleski would be the author informed. For much more please select the following links
Depuy Hip Recall Attorney
Depuy ASR Recall
Related Articles – Asbestos Exposure, Mesothelioma Cancer, asbestos attorney, lawyer, class action lawsuit lawyers, law suit, suite, law firm, legal firms, litigation, Treatment, ,
Email this content with a Friend!
Receive Articles like this one direct to your email box!Subscribe without spending a dime today!
No comments:
Post a Comment